A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Artiva Biotherapeutics, Inc.
H. Lee Moffitt Cancer Center and Research Institute
Radboud University Medical Center
National Institutes of Health Clinical Center (CC)
Intima Bioscience, Inc.
Intima Bioscience, Inc.
University of Chicago
M.D. Anderson Cancer Center
Essen Biotech
Washington University School of Medicine
University of California, Davis
TCRCure Biopharma Ltd.
ImCheck Therapeutics
Curacell Holding AB
Alaunos Therapeutics
Hadassah Medical Organization
Medicenna Therapeutics, Inc.
Indapta Therapeutics, INC.
Nova Scotia Health Authority
Essen Biotech
Essen Biotech
Essen Biotech
Essen Biotech
Essen Biotech
Tongji Hospital
Zhujiang Hospital
Washington University School of Medicine
Erasmus Medical Center
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Herlev Hospital
University Health Network, Toronto
Fred Hutchinson Cancer Center
Nantes University Hospital
National Institutes of Health Clinical Center (CC)
University of Michigan Rogel Cancer Center
Immetacyte Ltd
GC Cell Corporation
St. Anna Kinderkrebsforschung
Herlev Hospital
Herlev Hospital
University of Pittsburgh
University of Virginia
National Institutes of Health Clinical Center (CC)
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
University of Virginia
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota